Experimental combo targets Hard-to-Treat HPV cancers
NCT ID NCT03260023
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs—TG4001 (a biologic that targets HPV) and avelumab (an immunotherapy)—in people with advanced HPV-16 cancers that cannot be removed by surgery or cured by radiation. The trial has two phases: first, to find a safe dose, and second, to see if the combination shrinks tumors better than avelumab alone. About 143 participants with cervical, anal, penile, or vulvar cancers are being enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TG4001 (a vaccine-like biologic) and avelumab (an immunotherapy drug)
What this could lead to
If it works, this could offer a new treatment option for people with advanced HPV-16 cancers that have stopped responding to other therapies.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants. The combination may cause serious side effects, and it is not yet known if it works better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV-RELATED CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Besançon
Besançon, France
-
CLCC Georges-François Leclerc
Dijon, France
-
Centre Léon Bérard
Lyon, France
-
Centre Paul Strauss - ICANS - Institut de cancérologie Strasbourg Europe
Strasbourg, France
-
Fundación de Investigación Biomédica Hospital Clínico San Carlos
Madrid, Spain
-
Fundación de Investigación biomédica H. 12 de Octubre
Madrid, Spain
-
Hopital de la Timone
Marseille, France
-
Hospital General de Valencia
Valencia, Spain
-
Hospital Virgen de La Victoria
Málaga, Spain
-
Hospital Virgen de las Nieves
Granada, Spain
-
Hôpital Saint André - CHU de Bordeaux
Bordeaux, France
-
Hôpitaux Civils de Colmar - Hôpital Pasteur
Colmar, France
-
I.C.O. Gauducheau
Saint-Herblain, France
-
I.C.O. Paul Papin
Angers, France
-
ICO Badalona - Hospital Germans Trias i Pujol
Badalona, Spain
-
Institut Claudius Regaud - IUCT - Oncopole
Toulouse, France
-
Institut Curie
Paris, France
-
Institut Gustave Roussy
Villejuif, France
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States